Short Description ALX Oncology develops cd47 blockade biologics to support healthy longevity.
Description ALX Oncology is a biotechnology innovator targeting the fundamental mechanisms of aging through cd47 blockade biologics. The company leverages advancements in immuno‑oncology and collaborates with leading institutions to translate cutting‑edge science into practical interventions. By focusing on science‑backed solutions, ALX Oncology aims to extend healthspan and improve quality of life across the globe.
Address 866 Malcolm Rd, Suite 100, Burlingame, CA, USA